No near-term catalyst—trial enrollment hasn't started. Monitor for first-patient-enrolled press release and eventual topline data (likely 2028+). The Ascletis China data derisks the mechanism somewhat but does not guarantee U.S. success. No tradeable event here.
Price Chart
Executive Summary
Sagimet announced its AURORA Phase 3 trial of denifanstat for moderate-to-severe acne is on track to begin enrollment in Q4 2026, with patient screening starting in October. This is a routine pipeline update with no new data—the trial is not yet enrolling and results are years away. The stock has historically been volatile on pipeline news, but this filing provides no catalyst for near-term movement.
Key Facts
- AURORA Phase 3 trial of denifanstat in moderate-to-severe acne on track to enroll first patient in Q4 2026.
- Trial to enroll ~800 U.S. patients (including ~450 adolescents) over ~6 months.
- Co-primary endpoints at 12 weeks: global assessment score, inflammatory lesion count, non-inflammatory lesion count.
- 40-week open-label extension follows the double-blind period.
- Denifanstat is an oral, once-daily FASN inhibitor; if approved, would be first innovative oral acne treatment in >40 years.
- License partner Ascletis already completed a positive Phase 3 in China with denifanstat (ASC40) for acne.
Financial Impact
No financial data provided; trial costs are R&D expense, no revenue impact for years.
Risk Factors
- Phase 3 failure risk: acne trials have high placebo response rates and co-primary endpoints are difficult to hit.
- Regulatory risk: FDA may require additional safety data given adolescent population.
- Competition: existing topical and oral treatments (isotretinoin, antibiotics, hormonal therapies) are well-established.
- Cash burn: no revenue, ongoing R&D spend without near-term approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3350295 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $9.95 $9.58 | ▼ −3.72% | ▼ −3.20% | $10.30 (+3.52%) |
Oct 7, 2026 19d ago | SC 13G | $8.92 $8.93 | ▲ +0.11% | ▼ −0.49% | $10.30 (+15.47%) |
Oct 1, 2026 25d ago | Press Release | $9.14 $9.03 | ▲ +1.20% | ▲ +1.88% | $10.30 (−12.69%) |
Sep 30, 2026 27d ago | Press Release | $9.88 $9.37 | ▲ +5.16% | ▲ +5.34% | $10.30 (−4.25%) |
Sep 30, 2026 27d ago | 8-K | $9.88 $9.37 | ▼ −5.16% | ▼ −5.34% | $10.30 (+4.25%) |
Sep 22, 2026 4w ago | Institutional Cluster | $11.09 $10.42 | ▼ −6.04% | ▼ −5.32% | $10.30 (−7.12%) |
Aug 25, 2026 9w ago | Press Release | $10.29 $10.86 | ▲ +5.54% | ▲ +5.52% | $10.30 (+0.10%) |
Aug 11, 2026 11w ago | 8-K | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $10.30 (+8.19%) |
Aug 11, 2026 11w ago | Press Release | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $10.30 (+8.19%) |
Jul 22, 2026 13w ago | Insider Cluster | $7.01 $7.07 | ▲ +0.86% | ▲ +0.75% | $10.30 (+46.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers